Li, D., Li, J., Johann, D.J. et al. Augmenting precision medicine via targeted RNA-Seq detection of expressed mutations. npj Precis. Onc. 9, 182 (2025). https://doi.org/10.1038/s41698-025-00993-8

Download citation.

Optimal lesioning is essential for successful MR-guided focused ultrasound (MRgFUS) thalamotomies targeting the ventral intermediate nucleus (Vim) for tremors. This study aimed to evaluate the relationships between postoperative lesions that overlapped with the Vim and surrounding structures segmented automatically and the treatment outcomes.

This study included 48 patients who underwent MRgFUS thalamotomy targeting the Vim for essential tremors. The Clinical Rating Scale for Tremor (CRST) score was examined preoperatively as well as 1 week, 3 months, and 12 months postoperatively. Adverse effects were also assessed 1 month postoperatively. Using automatic segmentation software and fiber tracking software, the authors retrospectively segmented the Vim and surrounding structures, including the internal capsule (IC), ventrocaudal nucleus (Vc), zona incerta (ZI), and dentato-rubro-thalamic tract (DRTT), using preoperative images. Additionally, they manually delineated the coagulated lesions using images taken immediately after MRgFUS thalamotomy. The relationships between the volume and location of lesions overlapping with these structures, CRST improvement rates, and the presence of adverse effects were examined.

The mean thalamotomy volume was 0.076 ± 0.042 cm³ (median 0.085 cm³). The median improvement in the CRST score in the affected upper limb at 12 months postoperatively was 68.8%. Although no correlation was observed between lesion volume and CRST improvement at 1 week postoperatively, a positive correlation was observed between lesion volume and CRST improvement at 3 and 12 months. At 12 months, the authors observed a moderate correlation between the volume of the lesions overlapping with the Vim and improvement in the CRST score. A slightly stronger correlation was observed between the percentage of the lesion volume and the Vim. No correlation was found between lesion volume and improvements in the IC, Vc, ZI, DRTT, or CRST score. However, the authors found that both total lesion volume and the volume of lesion within the IC were significantly associated with gait imbalance.

If it has seemed like more people you know are developing diabetes, you are right. The diabetes epidemic is not called an epidemic for nothing: According to the American Diabetes Association, over 10% of the U.S. population—approximately 38.4 million people—had diabetes in 2021, and 1.2 million more people get diagnosed each year.

Type 2 diabetes occurs when your body develops a resistance to insulin, the hormone that helps regulate glucose levels in your blood. Insulin is secreted by pancreatic cells called β-cells, and in T2D, they ramp up insulin production to try to regulate blood glucose levels, but even that is insufficient and the β-cells eventually become exhausted over time. Thanks to their importance, the functional β-cell mass, or the total number of β-cells and their function, determines a person’s risk of diabetes.

Β-cells are not homogeneous, even within a single individual, and consist of different “subtypes,” each with their own secretory function, viability, and ability to divide. In other words, each β-cell subtype has a different level of fitness, and the higher, the better. When diabetes develops, the proportions of some β-cell subtypes are changed. But a key question remains: Are the proportion and fitness of different β-cell subtypes altered by diabetes or are the changes responsible for the disease?

Weill Cornell Medicine researchers have discovered that PD-1—a molecule best known for putting the brakes on immune cells—also plays a critical role in helping T cells become long-term immune defenders in the skin. Early during infection, PD-1 acts like a steering wheel, guiding T cells to become protective resident memory T cells (TRM) that stay in place. These cells remember invading germs or cancer and quickly mount a response if that enemy reappears.

The preclinical findings, published July 29 in Nature Immunology, may impact how clinicians approach cancer treatments called immune checkpoint inhibitors. These drugs bind to PD-1 on the surface of T cells, releasing the brakes and unleashing the immune system to attack cancer cells.

Though immune checkpoint inhibitors are successful in treating melanoma, an aggressive skin cancer, about 40% of patients develop inflammatory rashes and itching in the skin or reactions in other epithelial tissues that cover internal and external surfaces of the body.